Perbak Capital Partners’s Johnson & Johnson JNJ Stock Holding History

Perbak Capital Partners’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,748	Closed	-$1.55M	–	211
2024 Q4	$1.55M	Buy	+10,748	New	+$1.67M	0.83%	30

Other funds holding JNJ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Perbak Capital Partners's JNJ Position: Q1 2025 in Review

Perbak Capital Partners sold out of Johnson & Johnson (JNJ) in Q1 2025, closing a stake of 10,748 shares — an estimated $1.55M sold.

Perbak Capital Partners first reported a position in JNJ in Q4 2024 and held it in 1 quarter. The position peaked at $1.55M in Q4 2024. 4,148 funds tracked by Wall St. Rank hold JNJ as of Q1 2025.

Perbak Capital Partners reported no remaining Johnson & Johnson position as of Q1 2025 after selling out during the quarter.
Perbak Capital Partners sold 10,748 Johnson & Johnson shares in Q1 2025, an estimated $1.55M.
Perbak Capital Partners first reported a position in Johnson & Johnson in Q4 2024 and held it in 1 quarter.
Perbak Capital Partners's Johnson & Johnson position peaked at $1.55M in Q4 2024.
4,148 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2025.

Based on Perbak Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.